Attempt to control the day of ovulation in cycling pony mares by associating a GnRH antagonist with hCG.
With the objective of controlling the day of ovulation, 40 mares were assigned to a control or three treated groups: A3d, A4d, and A5d. The treated groups received antarelix (Teverelix 0.01 mg/kg, i.v., twice a day) for 3, 4, or 5 days from the day the dominant follicle (F1) reached 28 mm (=D0), and one injection of hCG (1600 IU, i.v.) on D1, D2, or D3, respectively. Control mares received one injection of hCG when F1 reached 35 mm. Plasma LH, FSH, progesterone, and total estrogens were assayed. In the A3d, A4d, and A5d groups, 9 (90%), 6 (60%), and 5 (50%) out of 10 mares, respectively, ovulated on the expected day (i.e. between 24 and 48 h after hCG injection). In the control group, 7/10 (70%) presented the typical response to hCG. For 3 mares in both the A4d and A5d groups, the dominant follicle at the time the treatment was started did not ovulate and ovulation was postponed for between 11 and 15 days after the end of treatment. In the treated mares, the LH surge was abolished, and total estrogens were depressed during the preovulatory peak but the concentrations of FSH were not modified. Endocrine parameters were not altered in postponed cycles. Fertility did not differ in treated and control cycles. These results demonstrate that in mares: (1) ovulation can be programmed on a specific day of a 3-day period, with a success rate of 67%, by a treatment associating antarelix and one injection of hCG; (2) nevertheless in 20% of cases the dominant follicle regresses and does not ovulate; (3) for these mares ovulation is postponed by approximately 2 weeks; (4) terminal growth of the preovulatory follicle only requires low circulating concentrations of LH but atresia induced by a GnRH antagonist is significant when this treatment is administrated for more than 18 h.
Briant
C
C
Physiologie de la Reproduction et des Comportements, Institut National de la Recherche Agronomique, UMR 6175 INRA-CNRS-Université F. Rabelais de Tours-Haras Nationaux, Nouzilly 37380, France. briant@tours.inra.fr
Ottogalli
M
M
Guillaume
D
D
D000818:Animals; D006063:Chorionic Gonadotropin / Q000008:administration & dosage*; D004967:Estrogens / Q000097:blood; D005260:Female; D005640:Follicle Stimulating Hormone / Q000097:blood; D007987:Gonadotropin-Releasing Hormone / Q000037:antagonists & inhibitors*; D006727:Hormone Antagonists / Q000008:administration & dosage; D006736:Horses; D007986:Luteinizing Hormone / Q000097:blood; D009842:Oligopeptides / Q000008:administration & dosage; D006080:Ovarian Follicle / Q000033:anatomy & histology; D010062:Ovulation Induction / Q000379:methods / Q000662:veterinary*; D011374:Progesterone / Q000097:blood; D013997:Time Factors
D006063:Chorionic Gonadotropin; D004967:Estrogens; D006727:Hormone Antagonists; D009842:Oligopeptides; D007987:Gonadotropin-Releasing Hormone; D011374:Progesterone; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone; C084350:antarelix